CEO Kevin Sharer

Biotech drugmaker Amgen Inc. has introduced new CEO Bob Bradway to shareholders at the company's annual meeting, with retiring CEO Kevin Sharer stepping down after a decade.Read Full Story

Amgen earnings per share estimates 1Q results 2012, Amgen Inc earning report april 24 2012, amgen stock prediction may 2012, amgen stock forecast 2012 : Amgen Inc., the world's biggest biotech company, will focus on recent deals, initial sales for new drugs and test data on some experimental ones when it reports its first-quarter results after the stock market closes Tuesday.WHAT TO WATCH FOR: Amgen CEO Kevin Sharer, who steps down at the company's annual meeting on May 23, will note a flurry...Read Full Story

Amgen Inc. (NASDAQ: AMGN), the world's largest independent biotech company, is scheduled to release its fourth-quarter financial results after the closing bell on Monday, January 24, 2011. Analysts, on average, expect the company to report earnings of $1.10 per share on revenue of $3.80 billion. In the year ago quarter, the company reported earnings of $1.05 per share on revenue of $3.81 billion. Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers...Read Full Story

Amgen Inc. (NASDAQ: AMGN), the world's largest independent biotech company, is scheduled to release its fourth-quarter financial results after the closing bell on Monday, January 24, 2011. Analysts, on average, expect the company to report earnings of $1.10 per share on revenue of $3.80 billion. In the year ago quarter, the company reported earnings of $1.05 per share on revenue of $3.81 billion. Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and delivers...Read Full Story

In May 2010 we presented a price model for Amgen Inc. (AMGN). It was based on the monthly (adjusted for dividends and splits) closing prices between June 2003 and March 2010. Today we revisited the model and found that it is still valid with almost the same coefficient. (Our concept and quantitative approach are described in the paper “Modelling share prices of banks and bankrupts” published in Theoretical and Practical Research in Economic Fields, ASERS, vol. I(1(1)_Summer), pp. 59-85...Read Full Story

In May 2010 we presented a price model for Amgen Inc. (AMGN). It was based on the monthly (adjusted for dividends and splits) closing prices between June 2003 and March 2010. Today we revisited the model and found that it is still valid with almost the same coefficient. (Our concept and quantitative approach are described in the paper “Modelling share prices of banks and bankrupts” published in Theoretical and Practical Research in Economic Fields, ASERS, vol. I(1(1)_Summer), pp. 59-85...Read Full Story

NEW YORK (Reuters) - Amgen Inc's chief executive met with the top executive of Swiss biotech firm Actelion Ltd to discuss his interest in Actelion, but made no offer for the company, Bloomberg reported on Sunday, citing three people with knowledge of the situation.Amgen CEO Kevin Sharer and Actelion CEO Jean-Paul Clozel met last week, according to the Bloomberg report.One source told Bloomberg that Sharer was looking to gauge Clozel's interest in a deal. Another person said that Clozel would...Read Full Story

Kevin Sharer, who has run Amgen Inc., the world’s largest biotechnology company, for the past decade, will hand the reins to Robert Bradway, president and chief operating officer, in May.Read Full Story

NEW YORK (Reuters) – Amgen Inc's chief executive puts With The top executive of Swiss biotech firm Actelion Ltd to Discuss His interest in Actelion, goal made no offer for The Company, Bloomberg Reported on Sunday, Citing Three People with Knowledge Of The situation. Amgen CEO Kevin Sharer and Actelion CEO Jean-Paul Clozel puts last week, According To The Bloomberg report. One source Bloomberg Told That Sharer WAS looking to gauge interest in Clozel's a deal.Another person Clozel Said...Read Full Story

Momenta Pharmaceuticals Announces Completion of Public Offering of Common Stock CAMBRIDGE, Mass. — Momenta Pharmaceuticals, Inc. , a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it has completed the previously announced underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $ 14.35 per share. Read more on GlobeNewswire via Yahoo! Finance WuXi PharmaTech Presents 2010 Life Science and...Read Full Story